24/7 Wall Street
11 Aug 2026, 16:50 UTC · 13w ago
Legend Biotech Gains 6% on Q2 Earnings Beat as Adjusted EPS Doubles Consensus
Impact · against what's priced in
Legend Biotech's first profitable quarter and strong CARVYKTI sales growth serve as a fundamental de-risking event and a catalyst for a valuation rerating. While JNJ benefits from the reiterated $5B peak sales target, the news is less material for BMY and NVS as it primarily validates the commercial success of a competitor or a secondary partner program.
- LEGN+0.80
No priced-in read yet





